| Ono Pays Kai $13M for Japanese Rights to Phase II Secondary Hyperparthyrodism Drug - Genetic Engineering News |
|
|
Genetic Engineering News KAI-4169 is also in preclinical development as a transdermal patch product for daily administration in the treatment of stage 3 and 4 CKD-MBD predialysis patients, ESRD (stage 5 kidney disease) patients receiving peritoneal dialysis, renal transplant ... KAI Pharmaceuticals Signs Agreement for Development and Commercialization of |